October 26, 2022

WEST CHESTER, Pa.–Data will be presented by R Yang and colleagues from the Guangxi Medical University Cancer Hospital and H Gabra from Papyrus Therapeutics Inc demonstrating that intravenously administered rOPCML-Fc has excellent tumor targeting affinity forhuman ovarian cancer patient derived xenografts (PDX) and produces strong dose dependent monotherapy efficacy both in-vitro and in-vivo.  Intravenous treatment at 10mg/kg over 4 weeks showed a 93% reduction in tumor volume without any obvious toxicities as judged by lack of differences in animals’ activities and weight in treated animals,  as compared with control vehicle treated animals.

Chief Scientific Officer Professor Hani Gabra commented “We are excited to present these data which confirm that our approach to the intravenous restoration of tumor suppression function is indeed feasible, efficacious and safe using our recombinant engineered Fc fusion  Opioid Binding/Cell Adhesion Molecule-like [rOPCML]. These encouraging results are consistent with data generated by Papyrus and support the company’s effort to develop novel extracellular tumor suppressor therapies.”

Abstract number 202
Session Title Molecular Targeted Agents 2
Session Date October 27, 2022

About Papyrus Therapeutics Inc.: Papyrus Therapeutics Inc. [West Chester, PA, USA] is an emerging Biopharma company developing novel tumor suppressor based therapies. Papyrus’ lead therapeutic, PYTX-004, is a modified recombinant Fc fusion of Opioid Binding/Cell Adhesion Molecule-like [rOPCML]. OPCML is a broadly acting tumor suppressor that is epigenetically silenced in over 44% of all solid cancers, leading to tumor invasion and metastasis through deregulation of apoptosis, epithelial-to-mesenchymal transition and cellular migration acting at the external leaflet of the cancer cell membrane, interacting with the extracellular domain of receptor tyrosine kinase inhibitors. Classic receptor tyrosine kinase [RTK] inhibition using small molecules has proven to be highly effective in many cancers, but treatment resistance remains a significant challenge. Delivery of OPCML which works at the cell surface, can overcome this challenge by reconstituting normal RTK signaling within the tumor.


Dr. Paul Blake